GSK invests $139 million to expand production capacity for BENLYSTA (belimumab) in Rockville, MD

By May 3, 2017News

ROCKVILLE, Md., May 1, 2017 /PRNewswire/ — GSK today announced $139 million of new investment in its biopharmaceutical manufacturing site in Rockville, MD to support growing demand for BENLYSTA® (belimumab) for adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.

View Original Article »

Join our Mailing List